Avinger, Inc. (NASDAQ:AVGR) Short Interest Down 39.5% in November

Avinger, Inc. (NASDAQ:AVGR) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 65,000 shares, a decrease of 39.5% from the October 31st total of 107,400 shares. Based on an average daily trading volume, of 227,300 shares, the short-interest ratio is currently 0.3 days. Currently, 2.4% of the company’s stock are short sold.

Avinger Trading Up 0.9 %

Shares of AVGR traded up $0.01 during midday trading on Friday, hitting $0.84. 14,313 shares of the company’s stock traded hands, compared to its average volume of 94,880. Avinger has a 1 year low of $0.70 and a 1 year high of $5.45. The firm’s fifty day moving average is $0.88 and its 200-day moving average is $1.41. The stock has a market capitalization of $2.69 million, a price-to-earnings ratio of -0.08 and a beta of 1.15.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.21. Avinger had a negative return on equity of 5,527.11% and a negative net margin of 261.06%. The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $1.60 million. During the same quarter in the prior year, the business posted ($2.92) EPS. On average, equities research analysts anticipate that Avinger will post -4.69 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Avinger in a report on Tuesday. They set a “hold” rating for the company.

Institutional Trading of Avinger

An institutional investor recently bought a new position in Avinger stock. Armistice Capital LLC bought a new stake in Avinger, Inc. (NASDAQ:AVGR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned 2.57% of Avinger at the end of the most recent reporting period. Institutional investors and hedge funds own 18.30% of the company’s stock.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.